Rezolute, Inc. operates as a clinical-stage biopharmaceutical company dedicated to addressing serious unmet medical needs in rare and metabolic diseases. The company's pipeline is anchored by ersodetug (RZ358), an intravenously administered human monoclonal antibody currently in Phase 3 clinical trials for congenital hyperinsulinism and tumor hyperinsulinism. Additionally, Rezolute is developing RZ402, an oral therapy in Phase 2 trials targeting diabetic macular edema. Originally founded in 2010 and formerly known as AntriaBio, Inc., the company rebranded to Rezolute in 2017. It operates primarily within the United States and focuses on advancing its proprietary protein-based and small-molecule therapeutics through the clinical and regulatory approval process.
